Home / Transcripts / Arcutis Biotherapeutics, Inc. (ARQT) · February 25, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Transcript

February 25, 2026

NASDAQ US Health Care Biotechnology earnings 73 min

Earnings Call Speaker Segments

Brian Schoelkopf executive
#1

Thanks, Michelle. Hello, everyone, and thanks for being with us this afternoon as we go over the business update along with the financial results for our fourth quarter and the full year 2025. You can find the slides for today's call in the Investors section on Arcutis' website. Here with me today are Frank Watanabe, our President and CEO; Todd Edwards, our Chief Commercial Officer; Patrick Burnett, our Chief Medical Officer; and Latha Vairavan, our Chief Financial Officer. I want to remind all of you that forward-looking statements will be made during this call. Such statements carry certain risks and uncertainties, and our actual results could differ. We urge you to look over all of the company's filings with the Securities and Exchange Commission, which include descriptions of our business and risk factors. With that said, I'll turn things over to Frank so we can get today's call started.

Todd Watanabe executive
#2

Thank you, Brian, and I appreciate all of you taking the time to be with us today. To kick off this call, I'd like to walk through several important accomplishments and milestones from 2025 — a period defined by extraordinary expansion and advancement for Arcutis as we continue working toward our goal of helping people who live with chronic inflammatory skin conditions. After that, we'll hand things over to Todd for an update on the commercial side, then Patrick will cover R&D, and Latha will walk through our financial results. So, during 2025, we achieved major progress in cementing Arcutis' standing as a top-tier leader within the industry when it comes to delivering meaningful innovation in medical dermatology. Over the course of that year, we experienced strong growth in net product sales revenue, consistent gains in prescriptions, and solid expansion of market share throughout every approved indication and formulation of ZORYVE, also known as topical roflumilast. We feel deeply humbled by the growing numbers of healthcare practitioners and patients who are choosing to place their confidence in ZORYVE as an innovative, safe, and effective treatment option for chronic inflammatory skin conditions — a significant and welcome substitute for topical steroids. During 2025, ZORYVE delivered explosive revenue growth, reinforcing its standing as the #1 branded nonsteroidal topical treatment across every one of our approved indications: psoriasis, seborrheic dermatitis, and atopic dermatitis. ZORYVE stands apart from anything that came before it in treating chronic inflammatory conditions — it offers a reach and a profile no other drug has matched. It's an advanced topical, one that's targeted, and it works safely and effectively no matter how long someone uses it, no matter which area of the body is affected, and across a range of indications and age groups. Providers and patients these days keep pushing for new, safe options instead of topical steroids, and ZORYVE's unique characteristics have arrived right in the middle of that shift, which is what has fueled its impressive commercial momentum and results. In 2025, net product revenues reached $372 million — a 123% year-over-year gain versus 2024. The increase in revenue was driven by prescription volume that doubled compared with the prior year, and that has strengthened even more our leading position in the branded nonsteroidal topical category, where across our approved indications we now account for roughly 45% — a share that keeps expanding — of prescription volume. In 2025, ZORYVE's commercial momentum got a lift from FDA approvals: ZORYVE foam 0.3% for scalp and body psoriasis in patients 12 years of age and older, and ZORYVE cream 0.05% for atopic dermatitis in children ages 2 to 5 years of age. Those clearances — the fifth and sixth for ZORYVE that we've received — reflect our commitment to extending the drug's advantages to as many psoriasis, seb derm, and AD sufferers as we possibly can. With the green light for a wider use of ZORYVE foam, individuals coping with scalp psoriasis and involvement of other delicate regions gained an important new option; they can now apply a version of the product to any part of the body, which adds a fresh degree of ease when handling a long-term skin problem. We take particular satisfaction in the fact that ZORYVE cream 0.05% is now cleared for small children suffering from AD, given how frequently this ailment appears at an early age and how sizable the patient population is within that age range. There's been a major gap in care that went unaddressed for way too long, and being able to finally fill it with ZORYVE is something we take real pride in. During 2025, we submitted a supplemental NDA as well, covering ZORYVE cream 0.3% intended for pediatric psoriasis patients between the ages of 2 and 5, and the goal date for a decision on that filing is June 29 of this year; if the answer comes back yes, it would mark one more essential milestone in addressing what this young population, plus the moms, dads, and others who look after them, still need. Switching over to the clinical side, enrollment wrapped up during 2025 for INTEGUMENT-INFANT, a Phase II study looking at ZORYVE cream 0.05% among babies from 3 to 24 months old who have atopic dermatitis. At the start of this month, we were very happy to share encouraging top line findings from that trial, and Patrick will walk through those results afterward during the call. At this point, we're preparing to file that data with the FDA as we pursue another label expansion. We see this as one more significant step forward in our ongoing efforts to make sure we're able to help these very young, highly vulnerable patients, for whom there are virtually no treatments cleared by the FDA. Also during 2025, we began Phase II proof-of-concept trials involving ZORYVE foam 0.3% for vitiligo as well as hidradenitis suppurativa, or HS. That represents a meaningful move as we look into possible new indications, which would allow us to bring ZORYVE's advantages to more people who need therapies that actually work, and to get even more out of the pipeline-in-a-molecule potential that ZORYVE embodies. Finally, during the previous year, we filed an IND for ARQ-234 — our innovative biologic that holds best-in-class promise for tackling a significant unmet need in atopic dermatitis — as we aim to broaden our pipeline and further our goal of bringing meaningful innovation to people living with chronic inflammatory skin conditions. In summary, this has been a remarkable year of advancement, and we believe these achievements have laid the groundwork for a strong 2026 and far beyond. Naturally, none of this could happen without the remarkable skill, dedication, and perseverance of everyone at Arcutis. Before we continue, I want to pause and express my appreciation to every member of our team for the profound, ongoing commitment they show toward our company's mission and, most importantly, toward the patients we serve. Now let's turn to Slide 6. As a way to set up the remainder of what we'll discuss today, let me walk through the three-pillar corporate strategy we rolled out a few months back, which lays out how Arcutis will maintain growth both in the near term and over the long term. Across each of these three pillars, we've already seen progress; when it comes to growth, I just referenced the strong results from the INTEGUMENT-INFANT trial, along with our intention to seek a label expansion grounded in those findings. Also, Todd will fill you in on this shortly, but we recently shared news that we are growing our specialty sales team in dermatology to push ZORYVE even further, plus we decided to assume responsibility for promoting ZORYVE among primary care physicians and pediatricians. On the expand side of things, Patrick will go into detail soon, but our Phase II POCs for HS and vitiligo keep moving forward, and we expect to present data from those trials in the latter part of this year or the beginning of next, while we also assess further POC studies in other conditions. Last, we anticipate getting the first patients enrolled in the Phase I trial of ARQ-234 soon, and down the road we'll share those study results with investors. Taking these tangible actions to execute our strategy shows how dedicated and disciplined we are in making sure Arcutis is positioned well for success both now and over the long haul. Before I pass things to Todd and Latha so they can walk through our Q4 results in greater depth, I'd like to touch on several important things regarding the revenue guidance we provided at our Investor Day back in November. First off, we're raising our 2026 full-year net product revenue outlook. It used to be $455 million to $470 million, and now it's going up to $480 million to $495 million. That reflects the strong momentum behind ZORYVE that our fourth quarter results show, plus the investments we keep making in the franchise that the team will describe in more detail today. Throughout the year, we'll reassess our revenue guidance and might revise it if that becomes appropriate. Next, we didn't just deliver positive cash flow in Q4 as we said we would — we're also reaffirming that positive cash flow will be sustained every quarter through 2026, even while we keep boosting our investment in ZORYVE's growth and in our pipeline. With that, I'll pass the call to Todd for a commercial update on Q4.

L. Edwards executive
#3

Thanks, Frank, and hello everyone this afternoon. Moving over to Slide 8. Like Frank mentioned, ZORYVE kept up its powerful upward trajectory during 2025's last quarter, when we produced steady revenue gains powered by broader uptake of ZORYVE throughout the indications we have approval for. Net product revenues came to $127.5 million in Q4. That represents 84% growth versus the prior-year period and 29% growth sequentially compared with 2025's third quarter. The main driver behind that quarter-over-quarter revenue increase was ongoing rises in prescription volume, which reached 19%. That shows growing trust among clinicians and patients in ZORYVE as a reliable therapy spanning a wide range of inflammatory conditions. Though we remain early in the launch phase, the early pickup of ZORYVE cream 0.05% — for treating atopic dermatitis in kids between 2 and 5 years old after the fourth-quarter 2025 approval — has been encouraging. A channel inventory build also added a very minor amount during the period, roughly 2%, equaling $2.5 million of Q4 revenue, which should reverse in Q1. Price improvement during the fourth quarter also exceeded what we had expected, thanks to continued lower co-pay card usage as additional patients reached their deductibles and out-of-pocket maximums, which contributed the rest of our quarter-over-quarter expansion. Gross to net continues to be steady, sitting in the 50s, and we expect it to stay within that same band during 2026. In contrast with certain rivals in branded topicals, last year brought us no gross to net erosion whatsoever, and we expect nothing meaningful in the way of gross to net erosion as 2026 unfolds. We do expect a normal dip in net product revenues during 2026's first quarter relative to 2025's fourth quarter. That quarter-on-quarter sales decline will mostly stem from usual seasonality tied to patient deductible resets that push co-pay usage higher; this pushes our gross to net rate up to the high 50s during Q1, after which it should steadily get better across the year, finishing with the lowest gross to net in Q4, mirroring what happened in 2025. On top of that, demand during a couple of January weeks took a hit from winter storm burn, which was anticipated given a storm of that size. Together, these things will produce a sharper quarter-on-quarter drop in total product revenue from Q4 to Q1 than what we saw in 2025, when quarter-on-quarter demand rose because our AD launch offset the usual seasonal headwinds. This is purely a Q1 effect. As Frank told you before, our confidence in ZORYVE's ongoing growth and momentum for 2026 is strong and building, which is why we felt able to lift our guidance range this early in the year. Looking at Slide 9, you'll see that prescriptions filled each week, measured on a rolling 4-week average, came in at roughly 22,000 scripts — setting yet another record for the ZORYVE franchise. As we look forward over the next twelve months, we anticipate demand will stay robust and lasting, powered by the primary engine of ZORYVE's revenue expansion. The market access wins we've recently locked in with several national PBMs and health plans are what will drive continued volume growth in 2026; on the commercial side, a number of plans improved ZORYVE's access by widening coverage and making utilization management criteria more stringent—bringing them to just one step to a topical steroid. We also gained coverage with multiple Medicare Part D plans starting January 1, meaning roughly 1/3 of all Medicare Part D beneficiaries can now get ZORYVE through their insurance plan. So ZORYVE is now the only branded nonsteroidal topical that appears on those Medicare formularies, and that opens the door for us to reach patients covered by Medicare. From the very beginning at Arcutis, this has been one of our main goals, and these formulary wins really confirm that our strategy around differentiated pricing and access is working. Because Medicare formularies favor generic options such as topical corticosteroids, ZORYVE ended up in the non-preferred drug tier, meaning patients face higher co-pays or co-insurance than they would for preferred tier products. We're thrilled to broaden access to ZORYVE thanks to this milestone, though we expect demand may be somewhat muted given that ZORYVE sits in a non-preferred spot. Let's turn to Slide 10. The strong momentum we carried through Q4 and all of 2025 really shows how valuable ZORYVE has been. We're seeing more trust in our brand from doctors and patients alike, along with a wider change in how inflammatory skin diseases get treated — moving away from topical corticosteroids. On this slide, three charts show the key forces reshaping the treatment approach for inflammatory skin conditions. The left-hand chart shows that the branded nonsteroidal topical category keeps expanding significantly, taking share from topical corticosteroids, whose use is either flat or shrinking. Inside that branded nonsteroidal space, ZORYVE accounts for most of the growth. The middle pie chart shows the share shift coming from advanced targeted topicals growing faster than topical steroids. So today, branded nonsteroidal topicals make up 7% of all topical prescriptions, and that's against a pretty large 2025 base of 24 million prescriptions. That's real progress. And as volume keeps moving away from topical corticosteroids toward branded nonsteroidal topicals, growth ought to speed up. For every 1 point of share that shifts away from topical corticosteroids, the branded nonsteroidal topical segment gets roughly 15% volume growth. And last, the chart on the right side of the slide makes it obvious that ZORYVE is set to gain overwhelmingly from this displacement of topical corticosteroids, since we hold a strong and growing 45% share of branded nonsteroidal volume. During our Investor Day back in October, we laid out the peak sales guidance and restated how strongly we believe ZORYVE can grow into a brand worth multiple billions of dollars. That confidence stems from seeing a meaningful portion of the topical steroid space shift over to advanced, targeted topicals like ZORYVE. According to our calculations, every individual share point we capture in the topical market — where corticosteroids hold dominance — works out to about $150 million in extra revenue. Entering 2026, the evidence that this shift is underway is solid and keeps growing. Demand from both prescribers and patients keeps climbing steadily for safer, nonsteroidal options used to treat chronic inflammatory skin conditions. Across the big dermatology gatherings that took place during this year's first quarter, speakers repeatedly sounded one note: the field must look past topical steroids and embrace advanced targeted topicals. We stay favorably positioned to deliver a safe, effective option for anyone in search of one. Turning now to Slide 11. I want to take a few moments to go deeper on the dermatology sales force growth we shared recently, along with the advantages we expect it to deliver. Back in January, we said our dermatology sales force would grow by about 20%, bringing it to somewhere near 160 sales personnel. What we mainly aim to achieve through this growth is more frequent calls on mid-decile prescribers, all while avoiding any harm to or thinning of the engagement we maintain with the top decile dermatology clinicians who produce the most for us.

L. Edwards executive
#4

To put it differently, what we're trying to accomplish with this investment is to get the cadence of our dermatology sales force interactions right, since we already reach enough of this provider setting. To give you a clearer sense of our approach, through this expansion we've mapped out prescribing patterns across various provider categories. High-decile prescribers make up a comparatively small group, yet as you can see, they account for the greatest volume of potential ZORYVE patients. And note that we look at activity by total topical prescription writing, which takes in topical corticosteroids, rather than ZORYVE writing or nonsteroidal topical writing. The doctors in this group have an outsized impact when it comes to writing prescriptions—they account for a year's worth—and they've been our primary emphasis until this point. Back in mid-2024, when we grew our sales team following the atopic dermatitis approval, our coverage of these top-tier clinicians was already maxed out, so we'd given them a quick overview of what ZORYVE might do for the people they treat. As for the mid-decile prescribers, that cohort is bigger and frequently sees patients who fall within ZORYVE's approved indications, even if their volume isn't as extremely high as what we see from the high-decile group. Until this point, we had been reaching at least those clinicians too, but in order to focus on prescribers with the greatest potential, the frequency with which our sales representatives connected with them had fallen short of ideal and was lower than for high prescribers. With a larger sales team, we can bring how often we call on mid-decile prescribers up to an ideal level, which will build more awareness and adoption of ZORYVE among that group. To round things out, there is one last category: low-decile prescribers, who are much more — who are considerably more numerous than the other groups because they write so few prescriptions, and they rank lower in priority for our sales efforts. We've started bringing these extra reps on board to make our sales team stronger, and we're excited about the quality of the people joining us and what they'll accomplish once they're out in the field. We think the payoff from this spending will start showing up in the back half of the year, and we expect it to pay off within the first year as the team gets up to speed. Now let's look at Slide 12. One of the main pieces of our growth pillar is taking Arcutis' commercial footprint into primary care physician and pediatrician offices. Back in January we announced that we'd started assembling a dedicated sales force aimed solely at these clinicians. When ZORYVE was first being commercialized, we were launching new products and trying to build operating leverage. At that point, working through a partnership gave us a useful way to reach that part of the market while limiting our financial risk. Now we can take the lessons from that initial partnership and pair them with our own commercial strengths, which opens up a focused, accretive opportunity. That opportunity can grow over time as we keep expanding our operating leverage. The real question isn't whether this is worth pursuing — it's how to execute it in the best possible way. So we're moving ahead methodically, step by step, starting with a small pilot meant to refine how we go to market. From there, we'll expand in a measured way, staying sharply focused on the PCPs and pediatricians who represent the greatest value. For this launch, the initial sales organization we're building will consist of roughly 30 sales reps plus the supporting staff around them. This initiative stands apart from our dermatology sales force expansion, and it comes on top of it — that expansion continues to concentrate solely on generating growth inside dermatology practices. In moving into primary care and pediatrics, we bring 4 separate competitive edges that leave us well placed to deliver results and create real impact. First, a sharply targeted strategy aimed at high-volume, early-adopter PCPs and pediatricians, which sets this investment up to be accretive right from the start. Second, demonstrated reimbursement support strengths, among them our patient access infrastructure, which helps make sure prescriptions that get written end up getting reimbursed. Third, our capacity to draw on the core commercial model behind our dermatology success. And fourth, robust advocacy from dermatologists, which supplies meaningful specialist backing for PCPs and pediatricians. ZORYVE's distinctive profile — a safe, nonsteroid topical that can be applied anywhere on the body and for any length of time — gives primary care clinicians a degree of confidence that topical steroids generally don't inspire. As the movement away from topical steroids reaches past dermatology, we're positioned to gain from it. Although we started with a targeted pilot involving early adopters, we think ZORYVE's profile could eventually find broad resonance across primary care as well as pediatricians. I've reached Slide 13 now. Yesterday, we were thrilled to share that Max Homa has come aboard our Free to Be Me awareness campaign, telling his story of managing seborrheic dermatitis with ZORYVE foam. Tori Spelling is being joined by Max. She and her daughter Stella have been open about what they've gone through with atopic dermatitis and seborrheic dermatitis. They've also been encouraging those dealing with inflammatory skin diseases to talk with their healthcare providers about ZORYVE, which is described as a safe and effective option for long-term treatment of these chronic conditions. The awareness Tori and Stella have generated around treatment choices for atopic dermatitis and seb derm has been both broad and impactful. It has shown up in over 60 traditional news outlets, along with thousands of broadcast and radio TV airings. That has led to nearly 5 billion media impressions, in addition to reaching millions through social media on Instagram and TikTok. We're eager for Max to add further to these efforts. Judging by the media and social media coverage over the last 24 hours, it's already going extremely well, with more than 25 original articles generating over 400 million impressions. With that, I'll hand things over to Patrick.

Patrick Burnett executive
#5

Thanks, Todd. Moving to Slide 15 now. Making sure ZORYVE can reach the widest possible group of people living with psoriasis, seborrheic dermatitis and atopic dermatitis — and that they can benefit from this drug's distinctive profile — continues to be our number one priority. Supporting young kids who have plaque psoriasis, along with infants who suffer from atopic dermatitis, sits at the heart of that mission. Today I want to begin by calling attention to the encouraging top line data from the INTEGUMENT-INFANT Phase II study of ZORYVE cream 0.05% in infants 3 to less than 24 months of age who have mild to moderate atopic dermatitis, which we shared earlier this month. At week 4, 58% of participants on ZORYVE cream 0.05% hit a 75% improvement on the Eczema Area and Severity Index, or EASI-75; and notably, 1/3 of patients got to EASI-75 after just 2 weeks of treatment, showing a very fast and strong response — one that clinicians have already greeted with highly positive feedback. Now to safety. No treatment-emergent serious adverse events occurred, and just 1 patient left the study because of an adverse event, which reinforces how consistent the safety and tolerability profile of ZORYVE cream 0.05% is with what we already saw in the 4-week pivotal INTEGUMENT-PED clinical trial in children ages 2 to 5 years. Finally, remaining on Slide 15, you'll see pictures of a 10-month-old Latino boy enrolled in the study who achieved EASI-75 by week 4. It's obvious that at baseline he had considerable atopic dermatitis affecting his arms and legs, along with involvement of the face, which is very characteristic of infants suffering from atopic dermatitis. From my perspective as a dermatologist in practice, seeing this degree of swift and meaningful skin clearance in such young patients — a population that has traditionally been difficult to manage given how few therapeutic choices exist — is genuinely heartening. One thing worth highlighting: we saw enrollment for this age group move quite quickly—faster than what we normally see and beyond what we had projected—which tells us there's real demand for nonsteroidal choices among these especially fragile patients. The data from INTEGUMENT-INFANT look very encouraging, given that infants with atopic dermatitis are in urgent need of new options beyond topical steroids, and there are hardly any FDA-approved therapies for this population. Also, atopic dermatitis tends to show up early in life, which sets it apart from other inflammatory skin diseases. In the U.S., close to 10 million kids live with atopic dermatitis, and about 60% start showing symptoms within their first year. Looking just at the trial's age bracket — babies from three to twenty-four months — roughly a million patients receiving prescription topical treatment could benefit from improved therapies. Treating AD in these youngest groups brings particular difficulties: their skin is more delicate, and the disease typically involves a larger share of their overall body surface than it does in teens or grown-ups. That means a higher chance of the drug entering the bloodstream. As a result, when it comes to these tiny infants, moms and dads are usually quite concerned about potential side effects from topical steroids. Those worries stretch from how long-term steroid exposure might affect a child's growth and bone development all the way to more immediate issues, such as putting the product on a child's face, where keeping it away from the eyes and mouth can be hard to manage. Because this patient group is so large and there's such a pressing need for treatments that are both safe and well tolerated, we have been steadily working toward expanding the label for ZORYVE into younger age groups of children who have atopic dermatitis. One thing that stands out about the INTEGUMENT-INFANT results is that we are getting nearer to having a product on the market that can treat people with chronic inflammatory skin conditions, atopic dermatitis among them, throughout the entire span of life, from infancy to adulthood. What that means is a nonsteroidal option will exist that shields patients starting at the earliest age from steroid exposure, while still effectively addressing their skin conditions. Let's turn to Slide 16. We've already started having conversations with pediatricians regarding the approved indication we currently have, which covers atopic dermatitis in patients aged 2 to 5. And the INTEGUMENT-INFANT data, along with the PDUFA date we're waiting on for 2- to 5-year-olds in psoriasis, assuming approval comes through, both make the case for our in-house sales team to reach out to pediatricians even more. Now that this steroid alternative has been demonstrated to be both safe and effective, once it gets approved for infants, and as pediatricians grow comfortable prescribing ZORYVE to, let's say, a 12-month-old with atopic dermatitis, they'll be more inclined and more ready to prescribe it to an older kid or an adolescent as well. Todd brought it up earlier, and I'll build on that: the first rollout of ZORYVE cream 0.05%, which is indicated for kids between the ages of 2 and 5 who have atopic dermatitis — about 1.8 million patients fall into that group — has gotten off to a promising start. Getting this meaningful new treatment choice in front of clinicians is something we're keen to continue doing, and even more so, we want to reach pediatric patients along with those who look after them. Later on, we plan to share the full findings from the INTEGUMENT-INFANT study at a medical conference. Using those results as our foundation, our plan is to submit an sNDA for ZORYVE cream 0.05% in infants at some point during this year's second quarter. In addition to atopic dermatitis, we have a label expansion effort underway for pediatric patients with plaque psoriasis. Although the group of patients in question is not as large as the pediatric AD group, an urgent demand persists for improved treatment options, and we are working to address it. During the third quarter of the prior year, we shared news that a supplemental NDA had been filed for ZORYVE cream 0.3%, with the goal of expanding its approved use to plaque psoriasis treatment in children aged 2 to 5. A PDUFA date of June 29 has been assigned to us, and we await the FDA's ruling with anticipation. Should the agency grant approval, ZORYVE cream would become the first and only topical PDE4 inhibitor cleared for plaque psoriasis in patients as young as 2, giving children and those who care for them a valuable option beyond topical steroids and vitamin D analogs. If we end up securing label expansions for these younger groups in atopic dermatitis and plaque psoriasis, then maintaining an in-house sales team focused on primary care and, just as importantly, pediatric clinicians is going to prove extremely useful as we work to inform healthcare providers about ZORYVE as a therapeutic alternative to topical corticosteroids. Alongside the clinical development work aimed at bringing ZORYVE to additional pediatric patients, we're also still assessing opportunities for generating incremental data that would further reinforce the indications we currently have approved. During our Investor Day, we shared a case report showing how effective ZORYVE was in treating nail psoriasis. That's a solid illustration of how incremental data generation might further reinforce our existing indications, and we're eager to share more updates as the year goes on. Moving to Slide 17. From the very beginning, going after new patient populations that could benefit from ZORYVE has been a central pillar of our clinical development strategy. The 5 approvals we've obtained since first getting plaque psoriasis approved in 2022 demonstrate exactly that. Through those, our indications have grown to cover seborrheic dermatitis and atopic dermatitis, while the approved ages for psoriasis and AD patients have been brought down.

Patrick Burnett executive
#6

There are solid grounds for thinking that still other skin conditions could see a response to ZORYVE, and that even more individuals could gain from it — this is what the expand pillar of our strategy, which Frank pointed to when today's call began, stands for. Backing this up is what we know about how ZORYVE works: its anti-inflammatory and antipruritic effects apply broadly, plus it may help shield melanocytes, and we also have direct, continuing input from practitioners out in the field describing what they see with ZORYVE in real-world use. Along those lines, our Phase II proof-of-concept work keeps moving forward with ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, or HS, and subjects are still being enrolled. Both vitiligo and HS are chronic inflammatory skin conditions where patient needs remain substantially unmet. These amount to merely 2 illustrations among several indications where ZORYVE has shown encouraging early signals as a promising therapy. That evidence led us to launch the proof-of-concept studies now underway in vitiligo and HS. We keep assessing other conditions in which ZORYVE could serve as a solid therapeutic choice. Whenever we opt to start further POC studies, the investment community will hear about it from us. Our expectation is to report, in the fourth quarter of 2026, a decision on whether to move vitiligo forward, along with the Phase II proof-of-concept data, and to give an advancement decision on HS, along with the HS Phase II data, in the first quarter of 2027. Turning to Slide 18, keep in mind that 3 cases appear there that illustrate the kinds of case reports and case series reaching us and shaping our expansion work for ZORYVE. The 2 patients shown on the left are children, both dealing with recalcitrant facial vitiligo. The girl in the upper left had already failed several topical therapies, among them topical steroids and topical JAK inhibitors, and after just 7 months on ZORYVE you can observe meaningful repigmentation. The boy in the lower left had likewise failed topical steroid treatment before, and he displays a good response after merely 5 months on ZORYVE. Over on the slide's right-hand side is a 31-year-old woman with Hurley Stage 1 HS whose HS cleared completely — pain and itch included — after only 4 weeks of ZORYVE treatment, alongside 2 non-inflammatory medications. In the lower right, you can also read details on 2 other mild HS patients whose results after ZORYVE were similarly striking. It's easy to see what fuels the enthusiasm clinicians keep expressing as they independently explore these novel uses for ZORYVE. Now to Slide 19. As I've mentioned during today's remarks, and as the slide lays out, we expect several near-term clinical catalysts over the coming year. Significantly, one of these clinical activities is moving ARQ-234 forward, our novel biologic aimed at CD200R, which carries best-in-class potential for addressing a substantial unmet need in atopic dermatitis and possibly other inflammatory skin diseases. Given the heightened attention that newer AD pathways like OX40 have drawn lately, we’re eager to advance ARQ-234 into clinical testing so we can confirm whether it could deliver a substantial treatment step forward for AD patients whose disease is more severe. This initiative now sits within our third pillar, build, which covers our work to grow the clinical pipeline past ZORYVE. We anticipate dosing the first patients in the Phase I study of ARQ-234 shortly. With that, I’ll hand things over — pass the call to Latha for the financial update.

Latha Vairavan executive
#7

Thanks, Patrick. Now I'm on Slide 21, where we're showing the financial results for the fourth quarter, both year-over-year and quarter-over-quarter. In Q4, net product revenues came to $127.5 million, an increase of 84% versus the fourth quarter of 2024 and 29% versus the third quarter of 2025. Other revenue in the fourth quarter totaled $2 million, coming from a milestone payment from Huadong. Cost of sales for Q4 was $11.7 million, versus $6.9 million in the fourth quarter of 2024, mainly because ZORYVE sales volume grew. During Q4, our R&D costs reached $20.5 million. That's a $6 million jump from $14.5 million in the same quarter of 2024, when a $3.3 million clinical trial credit brought those expenses down. Looking ahead to 2026, we expect R&D spending to climb as we continue pushing forward with clinical development work tied to ZORYVE life cycle management and kick off the Phase I study for ARQ-234. On the SG&A side, Q4 2025 saw $79 million in expenses, versus $57.6 million during last year's comparable period. That works out to a 37% rise, driven by what we're putting into ongoing commercialization efforts behind ZORYVE. Looking ahead to 2026, our SG&A line should rise, since we'll continue putting incremental dollars behind ZORYVE commercialization. That includes growing the dermatology sales force and standing up the first phase of our in-house primary care and pediatric sales team, which Todd described earlier. Turning to the quarter, we posted net income of $17.4 million. A year ago in the same period we had a net loss of $10.8 million, and in the third quarter of 2025 net income came to $7.4 million. We still anticipate generating positive cash flow each quarter throughout 2026, though results may swing between operating income and an operating loss from one quarter to the next, largely because of noncash items such as stock compensation and milestone payments. During our Q3 financial update, we said this was coming, and it played out: ZORYVE's net sales kept climbing, and because we stayed tight on spending, we hit a cash flow positive position in the fourth quarter of 2025. That arrived sooner than we'd projected, and it's a significant milestone and accomplishment for the company. On December 31, 2025, our cash and marketable securities totaled $221.3 million, and operations generated positive cash flow of $26.2 million for the period. Our total debt sits at $108 million, and through the middle of 2026 we can, at our discretion, pull down an additional $100 million, either fully or partially, which provides us with operational flexibility. Thanks to how well the ZORYVE franchise is performing, plus the cost advantages we're building, we'll be able to put money back into the business to keep it growing steadily in the coming years. Let's move on to how we did for all of 2025. I'm now on Slide 22. Looking back at 2025 as a whole, our net product revenues reached $372.1 million. That represents a 123% increase, amounting to $205.5 million above what we recorded in 2024. What drove most of this dramatic year-over-year jump in product revenues was greater demand for the ZORYVE line of products. For 2025, additional revenue came to $4 million. That compares with $30 million during 2024, when a $25 million upfront payment related to the Sato Japan license agreement came in. Cost of sales reached $36.7 million in 2025, up from $19.1 million the year before, driven by increased ZORYVE unit volume. R&D spending was essentially flat year over year, at $77.1 million for 2025 compared with $76.4 million for 2024, as higher roflumilast development costs in pediatric atopic dermatitis were largely offset by reduced preclinical development costs. SG&A expenses climbed 20% during 2025, totaling $274.6 million. The primary reason for the rise compared to last year was that we kept ramping up spending on sales and marketing around getting ZORYVE commercialized. We posted a net loss of $16.1 million for 2025, versus a net loss of $140 million for 2024. That $123.9 million improvement in net loss stemmed from net product sales expanding at a pace far beyond that of our expense base. Although costs continue climbing due to strategic investments that deliver positive ROI and are accretive, our top line revenue is growing much more quickly, which points to greater operating leverage we anticipate enjoying down the road as ZORYVE keeps following its growth trajectory. Let's now turn to Slide 23. Like we said before, there are several catalysts close at hand that should create value throughout this business. Building on what Patrick laid out about anticipated clinical and regulatory milestones, we also expect commercial momentum to keep building during 2026. For this year, our projection for net product sales across the full twelve months falls between $480 million and $495 million. Compared with the guidance range we shared at our Investor Day last October, that works out to $25 million more at both the upper and lower ends. The basis for our increased full-year sales outlook is twofold: first, the ongoing momentum behind ZORYVE that today's Q4 figures make clear, and second, the money we're putting into the franchise—including the dermatology sales force expansion Todd walked through earlier. One thing to keep in mind: this investment will need time before it shows results, becoming apparent in the latter half of the year, while quarters 1 and 2 will probably see little meaningful effect. We feel sure that the investments we outlined today—aimed at growing, building, and expanding our business—can be covered by money generated from our core ZORYVE operations, all while keeping cash flow in positive territory. We'll stay careful with shareholder capital and keep close watch over how we allocate it, so that this scenario comes to pass. It's a real advantage that we hold a set of high-ROI investment prospects alongside a franchise like ZORYVE that brings in cash. With that, I'll hand the floor to Frank for a few closing remarks.

Todd Watanabe executive
#8

All right. Thank you, Latha, and I appreciate everyone being here with us today. Given how much we accomplished and how far we've come in 2025, plus the various catalysts we expect to drive value throughout the business in 2026, our excitement has never been greater — about what lies ahead for ZORYVE, for the company as a whole, for our capacity to build shareholder value, and above all, for our capacity to deepen the difference we make in the lives of people dealing with chronic inflammatory skin diseases. We're eager to share further updates with you as the year goes on, and we're grateful for your ongoing interest in the Arcutis story as it continues to take shape; so with that, let's turn it over to Q&A.

Seamus Fernandez analyst
#9

Congratulations on those strong numbers. Frank, I was hoping we could address the news that came out from a possible rival in this space. My understanding is Incyte mentioned certain difficulties, or perhaps a need to bring OPZELURA's price down, so that access could be better; from what I can tell, access doesn't seem to be an issue for ZORYVE; so I'd like to hear your perspective and remarks regarding what's happening right now in the market, both in the AD category and in your wider push to keep gaining ground versus topical steroids.

Todd Watanabe executive
#10

Seamus, thank you. That's another excellent question. Given what we heard this morning, this isn't unexpected. It is somewhat amusing that we're speaking from separate areas of the hotel. Perhaps, to offer a different angle, I'll have Todd weigh in on this, since you already got my response earlier today.

L. Edwards executive
#11

Absolutely, glad to take that one. Seamus, I appreciate you raising it. To begin with, when it comes to steps we're taking to broaden access in 2026, we don't expect any meaningful deterioration in our gross-to-net as a result. As we noted before, 2025 saw us secure considerably better access. On the commercial side, over 80% of patients covered by commercial insurance can get ZORYVE, and that access is high quality — in other words, a single-step edit through a steroid. We also mentioned previously that our Medicaid access is outstanding, with a single-step edit or less applying to more than half of the patient population in Medicaid for ZORYVE; and then there were our Medicare Part D wins, just announced, taking effect January 1. So access has been optimal for us, and to keep it that way, we don't foresee needing to provide any extra rebates in 2026 that would hurt our gross-to-net. I'd also like to point out that we built our pricing strategy specifically to support this type of reimbursement, which enables substantial patient access. Our strategic approach to pricing has mattered, and we can now observe that in access throughout both commercial insurance and government insurance.

Todd Watanabe executive
#12

Yeah, so perhaps I'll jump in and enjoy a small victory lap here. Like I said before, when we first launched, plenty of investors doubted our access approach and wondered why we chose such a distinct route compared with others in the branded topical arena. I'd argue strongly that the past 3 years have confirmed the soundness of the strategy we took. As Todd just recapped, we've now secured excellent access across commercial, Medicare, and Medicaid. That has arrived alongside a quite sensible and steady gross to net, sitting in the 50s, and we anticipate it will stay at that level. So I believe the market has truly demonstrated that we picked the correct strategy right from the start, and it's benefitting not just our investors but patients as well.

Seamus Fernandez analyst
#13

Excellent. Let me squeeze in a single brief follow-up here. What I want to dig into ties more to certain rulings — decisions from federal courts concerning rebate mechanics, plus some labor law developments that are casting doubt, as I see it, on parts of the rebate framework; yet word on the street is that altering how today's market operates, given how entrenched the GPOs are, would prove genuinely difficult. So when you evaluate these marketplace shifts, do you anticipate that any of these fresh developments and adjustments could open the door to favorable movement on the access side?

Todd Watanabe executive
#14

Sure. Seamus, that one's quite interesting as well. Right now, I'd say Washington is buzzing with conversation about the reimbursement landscape we currently operate in; in the budget bill that got through last month, we noticed what I'd call initial movement toward substantive overhauls of the existing payer system, though those measures were fairly modest. Talk keeps circulating both on Capitol Hill and within the administration regarding modifications to the PBM space — pardon me, to the reimbursement space, to put it more generally. Honestly, it feels far too soon to predict what Washington will ultimately pursue there. No matter how things play out, our confidence holds that Arcutis occupies a strong position both to keep ZORYVE broadly accessible for patients and to deliver a sensible return for those who invest with us. Still, speaking just for myself, I believe it's way too soon to forecast how all of this will ultimately resolve when it comes to genuine reform of the U.S. insurance system.

Tyler Van Buren analyst
#15

Ekeno O'Connor here, filling in for Tyler. Nice work on the quarter, everyone. We saw that your presentation didn't include separate sales figures for every SKU. Could you speak to that, along with any growth trends you anticipate across the various SKUs as we head into 2026?

Todd Watanabe executive
#16

Yes, absolutely. Todd, would you like to handle that question?

L. Edwards executive
#17

Sure, I'll take that one. Yeah, as we touched on earlier, every part of the portfolio grew, and each of the SKUs posted substantial gains. When you break down how those SKUs performed, demand climbed particularly for the ZORYVE foam, since we now have 2 indications for it — seborrheic dermatitis along with scalp and body psoriasis — but even so, the growth we've seen across all the products has been quite encouraging. And going into 2026, and all the way through that year, we expect the portfolio to keep expanding. Every one of these products stands apart, both compared with the vehicle and compared with what patients have had available, because dosing happens once a day, application is possible anywhere on the body and for whatever duration, and the results are outstanding when it comes to controlling these inflammatory skin conditions over the long term. So we're eager to see the portfolio keep growing as 2026 unfolds.

Todd Watanabe executive
#18

Yeah. One thing I'd like to mention — for those of you on the investment side, when you examine the prescription breakdown by SKU, since our SKUs differ, that gives you a fairly solid picture of the split, correct? Across the SKUs, gross-to-net figures are basically identical. When we first bring something to market, say 0.05%, there's somewhat of a delay, though it catches up with the remaining SKUs quite fast. So by checking the SKU split, you can get a reasonably clear read on the situation. The foam is the single outlier, because it carries 2 separate indications; and honestly, at this stage we lack sufficient data to separate seb derm from scalp psoriasis. My guess is that over time we may develop a sharper estimate of that, and we'll pass it along to the investment community; however, full transparency will never be possible given that it's one and the same SKU.

Latha Vairavan executive
#19

Ekeno, one more thing from me: the breakdown of net sales does appear in the financial statements we filed, and we'd be glad to get those specifics over to you. As Frank mentioned a moment ago, net sales are itemized by SKU within those statements, so you're able to review them there.

Judah Frommer analyst
#20

Congratulations on how far things have come. I'm just wondering if we could hear a bit more about why you feel sure enough to lift the guidance for the entire year. Clearly, the fourth quarter was solid, yet we're about to enter a first quarter that sounds like it will be shaped by seasonality. So could you perhaps separate out the pieces — formulary access, your confidence in the sales force additions, and whatever else drove the revisions to the assumptions in your model?

Todd Watanabe executive
#21

Right; Todd, I don't want to overstay my welcome, so I imagine I'll hand this one to you as well.

L. Edwards executive
#22

Right, right. So let me sort of set the context here. First off, there's the outstanding momentum we're carrying into Q4; that pairs with the money we're putting into the franchise — number one, growing the dermatology field sales force, and we'll feel that effect during the back half of the year; on top of that, the spend on primary care pediatricians and our entry into that segment, again, lands in the back half of the year. Now regarding formulary access, like I said, our formulary access remains outstanding; last year we didn't — we'll bring that into 2026 as things move ahead; so as for how Q1 behaves, well, that's the usual seasonality you'd expect from any pharmaceutical product, including nonsteroidal branded topicals. Like I said, part of it comes from the deductible reset that kicks in when the year starts. And on top of that, patients switch insurance plans starting January 1, and that drives up co-pay utilization and consequently a bigger gross to net rate during Q1, which, as we said, sits in the high 50s; however, starting in Q1, that gross to net rate keeps declining, just like we observed in 2025, reaching its lowest point in Q4. We lifted the guidance. Our confidence in the performance is strong. It will materialize in 2026, and we anticipate quarter-over-quarter sequential growth as we move from Q1 through Q4, consistent with the restated guidance, and again, keeping in mind that the spending on the dermatology expansion and the PCP expansion will make themselves felt in the back half of the year.

Uy Ear analyst
#23

Nice work on the strong quarter. If you don't mind, I have a few questions. To start, I believe during Q4 you mentioned that growth from one quarter to the next was 29%, with roughly 19% of that stemming from Rx and 2% coming from inventory. That would suggest around 8% originated from pricing. I'm just curious — should we expect that kind of lift to persist throughout the year, and especially in Q4 of next year? That's my first one. My second one: you said you hold roughly 1/3 of Part D. Could you help us grasp what that means — like, how come you're in a position to secure that 1/3, and at what point could you capture the rest? And what was it regarding this specific 1/3 that made — that enabled, I suppose, access?

Todd Watanabe executive
#24

Todd?

L. Edwards executive
#25

Sure, that’s fine. Yes. As for what happened in the fourth quarter, your point is right about the 29%, with 19% coming from volume, and 2% — that was an inventory build we had, again, 2%, or $2.5 million, which we expect to reverse in Q1. Then the remaining piece was price benefit, driven by patients progressing more quickly through their deductibles, which brought down our co-pay card costs. We’ll see the seasonality in Q1 that we discussed. But beyond that, as we said, gross to net will keep getting better across the quarters through Q4 as patients begin reaching their out-of-pocket maximum, which cuts our co-pay card spending, and that usually is highest in Q1 and then steps down quarter by quarter to a lower cost for us, which brings our gross to net lower in Q4. As for Medicare Part D and the 1/3, how and why were we able to get there? There are 2 reasons. First is our strategic pricing. We set the price for ZORYVE so we could secure access across both government and commercial payers and PBMs. And second is that ZORYVE is highly differentiated. One is the portfolio we have, which no other branded topical company can provide, a portfolio of products across the disease indications that we can. The other is the substantial volume uptake we’ve seen in our commercial business, which is clearly recognized by the Part D plans, who understand there is demand from Medicare Part D beneficiaries for access to this kind of product, and that has led to us gaining that 1/3 of the Part Ds. As for the rest of Medicare Part D, we’ll keep working with the remaining plans and PBMs, but we don’t expect to pick that up until probably the first part of 2027, though we’ll work hard to try to pull that forward if we can.

Todd Watanabe executive
#26

It really is worth pausing to appreciate how significant securing Medicare access — and Part D access — truly is, correct? Getting branded items covered on Part D formularies happens very seldom for patients; and as Todd said during the call, we hold the distinction of being the sole branded topical included on formulary. These individuals are your grandmothers, your mothers. They are folks who merit access to medical innovation every bit as much as anybody else, perhaps even more. We take genuine pride in what we've achieved thus far in obtaining Medicare coverage, and we're eager to bring the rest of the Part D formularies aboard. I'd also like to point out to investors that Part D, in contrast to Medicaid, resembles commercial markets somewhat more closely, since numerous commercial plans administer the Part D plans. Consequently, formulary access must be secured from every separate Part D provider, which explains why it arrives unevenly, just as commercial coverage does.

Andrew Tsai analyst
#27

This is Brian calling in place of Andrew. Regarding HS as well as vitiligo, could you remind us what the primary endpoints are for each, and also which outcomes you would want to observe before advancing both into Phase III?

Todd Watanabe executive
#28

Of course. Patrick, would you like to handle that question?

Patrick Burnett executive
#29

Absolutely. As we head into Q4 with vitiligo — aiming toward a decision and the presentation of that data — and then Q1 for HS, our main goal is gaining real insight into how the response kinetics look for patients, since in both of these conditions the timing of that response matters a great deal. How long patients have needed to reach a response they consider meaningful has been a difficult issue, so that will be a central area of attention for us. Beyond that, because these trials are open-label, we also need to grasp what proportion of treated patients demonstrate meaningful clinical improvement by that point, which would let us form a reasonable estimate of what a pivotal trial might be expected to show when we then return to the standard endpoints you'd anticipate in a pivotal study for vitiligo and HS. Still, the profile we've observed — strong tolerability, once-daily dosing, and fast response, the pattern that has defined our efficacy and safety results across all 3 indications — is what we hope to reproduce here.

Serge Belanger analyst
#30

Nice work finishing 2025 on such a solid note. My first question is about the pediatric side of things. From what I understand, you've had a 0.05% cream on the market for close to 4 months now. Could you share a bit more about how much awareness exists and how ready prescribers are to write for it in that segment? Then, second, with sales forces growing in 2 areas and cash still building while cash flows stay positive, has your interest shifted when it comes to bringing a commercial asset into the sales team's bag?

Todd Watanabe executive
#31

I can handle the first one — actually, the second one, and then hand the first one to Todd so he gets a bit of relief. My view is that a commercial stage asset likely isn't our top priority at the moment. The main explanation is simply how many fresh opportunities we now have with ZORYVE, correct? Across roughly 3 years, we've secured 6 approvals; this year we anticipate at least 1 additional approval, maybe 2, based on how quickly the FDA moves on the 3 to 24 months; even so, plenty of effort remains before ZORYVE promotion is fully optimized; and the last thing I want is to place products into the bag that wind up pulling our focus away from our highest margin commercial opportunity, which is growing ZORYVE. So honestly, I'd say that isn't something we're prioritizing heavily. In my view, the true chance to build shareholder value lies, frankly, in assets that are further back in development, particularly those around mid-stage. Patrick and his group, along with Bethany and hers, have shown themselves to be a remarkably capable development organization; and we've got, what, 6 FDA approvals to our credit, plus 4 Health Canada approvals; for a company our size, that record is quite impressive, every one delivered on schedule, with zero CRLs. So if we can take a strong asset and place it with our development team, that strikes me as our best route to creating value, beyond keeping ZORYVE growing and pushing ARQ-234 forward. Now, Todd, would you mind weighing in on what we're seeing with pediatrics?

L. Edwards executive
#32

Yeah. When you look at just 0.05% atopic dermatitis in the 2 to 5 years old group, there's a real readiness to write a prescription for this product, and since it launched we've seen strong pickup. For that patient population, this is an excellent product. It gives you, again, one application per day, in a vehicle that's very soothing and moisturizing. It works very well; you can apply it anywhere on the body, for however long is needed. This product delivers long-term control of the disease and is a terrific choice when you want to move away from steroids. Caregivers, pediatricians, and dermatologists would rather not use steroids with patients in this age group. That's exactly where ZORYVE brings a meaningful value proposition, for both the caregiver and patient as well as for the provider. So the uptake has us quite encouraged, and the feedback keeps being very positive, from providers and also from patients.

Jin Law analyst
#33

Great to see the progress. I have a few questions. When it comes to that new 2026 guidance, how much does it account for possible sales gains in primary care and pediatrics, given that those efforts are now being brought in-house and you're also launching these pilot programs? So, I mean, considering how little Kowa contributed, I think that's the reason you ended that contract. If you can achieve improvement in that PCP and pediatrics segment, is there a chance 2026 sales could go even higher than what you guided?

Todd Watanabe executive
#34

I'd say it's likely a bit early to guess at how big the primary care contribution will be; that's something we'll keep guiding on. As Todd said on this call, our approach to primary care is very methodical and stepwise. We'll begin with a quite small team aimed at the highest value customers, so we can truly fine-tune our go-to-market strategy and determine the right way to reach this very large but very diffused opportunity in primary care and pediatrics, and then we'll scale as we figure that out. So how fast we scale that, and how fast it begins to inflect the top line, I think, is probably premature for us to speculate on.

Jin Law analyst
#35

All right, understood. And now, as a quick second question regarding those Medicare individuals: what would the out-of-pocket cost be for them under that non-preferred branded tier?

L. Edwards executive
#36

Yeah, Frank, I can take that one; so what you're asking is, when it comes to what Medicare beneficiaries pay themselves, what's the highest amount allowed under the cap? Assuming that's what you mean, come 2026, that cap stands at $2,100. That means someone has to cover the co-pay or coinsurance tied to their drug until reaching that $2,100 ceiling for out-of-pocket spending, after which the Part D plan picks up the cost of the products.

Todd Watanabe executive
#37

Correct. I'd simply build on what Todd said, and remind everyone that across all medications, the out-of-pocket total comes to $2,100, correct? That means for an older patient taking several drugs, the most they'll pay themselves over the year is capped at $2,100. There's also an option for patients to sign up for smoothing, and under that, the highest amount they'd owe in a given month equals 1/12 of $2,100 — so it stays quite manageable. When it comes to a ZORYVE prescription, the exact dollar figure really hinges on the patient's plan. It differs based on the insurance company as well as which plan the patient selected.

Douglas Tsao analyst
#38

Frank, maybe a fast follow-up on Kowa and that primary care opportunity. I guess, obviously, as you framed it, that represents a massive opportunity, and a multifaceted one at that. Was the issue simply that you believed they were not chasing the right strategy, and you sort of saw a different route forward? Or did it come down purely to retaining every bit of the economics for yourselves?

Todd Watanabe executive
#39

I would say it's not either of those. When we inked that Kowa deal, about 1.5 years ago, our financial position wouldn't let us build our own primary care team. Now we find ourselves in a very different place. Kowa is an entirely fine organization. But when something genuinely matters to you, going it alone is often the superior option, right? So given that our finances today let us manage this in-house, we concluded the best way to enhance shareholder returns was for us to run primary care and pediatric promotion ourselves. Like you said, we do keep all the economics from it, even though some costs arrive with that too. Even so, we're fairly confident we can pull this off in a way that turns accretive to our shareholders very quickly. With 66 FDA approvals under our belt for Health Canada approvals under our belt, that track record supports our confidence.

Douglas Tsao analyst
#40

Frank, let me ask a follow-up on that point. Does the traction you're observing with ZORYVE also reinforce your view that the company effectively plays two roles here?

Todd Watanabe executive
#41

Yes, without question. I'd also note that a portion of the initial experience we gained with Kowa helped build our confidence in this area. Among the physicians they had visited, there's a tremendous amount of enthusiasm — I'd say — regarding ZORYVE within primary care and pediatrics. They started holding speaker programs toward the close of 2025. And for anyone on this call who hasn't worked in the business, running speaker programs is extremely challenging nowadays. Honestly, how many people showed up to those programs caught us off guard, and I believe it demonstrates just how much interest exists within the primary care and pediatric communities. As we keep broadening our pediatric indications—moving to ages 2 to 5 for psoriasis and in time covering 3 to 24 months for atopic dermatitis—I expect that enthusiasm will only grow. That reinforced our belief that a genuine opportunity is here. Another key point worth remembering, which we brought up during the investor call, is that roughly 300,000 primary care providers practice in the United States, correct? For any business, that figure is enormous—and even more so for a company of our size. During the investor call, we discussed how roughly 5% of those providers generate around 1/3 of all topical prescriptions. So there's a highly concentrated, high-value group made up of primary care physicians and pediatricians. Our efforts will really be aimed at that extremely concentrated, highly productive slice of the market. We might also capture some volume in other market segments, but building a huge primary care sales force that calls on tens of thousands or hundreds of thousands of primary care providers isn't what we're after. For us, that simply isn't sensible. Our emphasis is going to be right at the sharp end, targeting primary care physicians who handle extremely large volumes of topical treatment prescriptions.

Todd Watanabe executive
#42

All right, I’ll be brief. As usual, I appreciate the excellent questions. I’m grateful that you took the time to join the call and hear what we had to say today, and we’re eager to speak with everyone again in 90 days with an update on the first quarter. Many thanks. Goodbye.

Operator operator
#43

This concludes today's conference call. Thank you for participating, and you may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arcutis Biotherapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arcutis Biotherapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.